Kahn Swick & Foti, LLC, a law firm led by former Louisiana Attorney General, Charles C. Foti, Jr., is reminding investors who have suffered losses in excess of $100,000 in MacroGenics, Inc. (MGNX) that the lead plaintiff deadline in the class action lawsuit against the company is fast approaching.
The lawsuit alleges that MacroGenics misled investors about the efficacy of its lead product candidate, margetuximab, in treating HER2-positive breast cancer. The company claimed that the drug was more effective than trastuzumab, a widely used treatment for the same condition, but failed to disclose negative information that would have impacted its stock price. When the truth came to light, MacroGenics’ stock plummeted, causing significant financial harm to investors.
Investors who meet the criteria and wish to serve as lead plaintiff in the class action lawsuit must file a motion with the court by a specified deadline. Failure to do so could result in the loss of their ability to participate in any potential recovery.
The law firm is dedicated to seeking justice for investors who have been harmed by corporate misconduct and is urging those affected by the MacroGenics scandal to contact them for more information on how to protect their rights.
If you believe you have a claim against MacroGenics, Inc. and have suffered significant financial losses as a result of the company’s actions, it is crucial to act quickly to ensure that you do not miss the opportunity to seek compensation. Contact Kahn Swick & Foti, LLC today for more information on how to join the class action lawsuit as a lead plaintiff.
Source
Photo credit news.google.com